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ABSTRACT 
BACKGROUND: This the first 5-year effectiveness study of publicly funded treatment for opioid 
use disorder (OUD) in England.  
METHODS: All adults initiating treatment in 2008/09 in all 149 local treatment systems reporting to 
the National Drug Treatment Monitoring System (n=54,347). Admission polydrug use sub-
populations were identified by Latent Class Analysis. The treatment outcome measure was 
‘successful completion and no re-presentation within six months’ (SCNR) analysed by multilevel, 
multivariable logistic regression and funnel plots to contrast outcome by treatment system.  
RESULTS: SCNR was achieved by 21.9%. Heroin and crack cocaine users were significantly less 
likely to achieve this outcome than patients who used heroin only (adjusted odds ratio [AOR] 0.90; 
95% confidence interval [CI] 0.85-0.95). Older patients (AOR 1.09; CI 1.07-1.11), those employed 
(AOR 1.27; CI 1.18-1.37) and those enrolled for longer treatment were more likely to achieve the 
outcome measure. After risk adjustment, the local treatment systems that achieved substantially 
better outcome performance (14/149) had a lower rate of opiate prevalence in the local population 
at time of study initiation (incidence rate difference [IRD] 4.1; CI 4.0-4.2), fewer criminal offences 
per thousand (IRD 28.5; CI 28.1-28.8) and lower drug-related deaths per million (IRD 5.9; CI 5.9-
5.9). 
CONCLUSIONS: In an English national study, one fifth of patients successful completed treatment 
for OUD and did not present for further treatment within six months. Longer time in treatment 
increases the probability of achieving and maintaining clinical benefit from treatment. After risk-
adjustment, an important minority of treatment systems achieve substantially better outcome 
performance. 
 
Keywords: Treatment effectiveness; opioid use disorder; national; prospective 
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1.  Introduction 
Heroin and non-medical opioids are associated with a substantial global burden of disease 
(Degenhardt et al., 2013). In the United States (US), it is estimated that 2.6 people per 1,000 aged 
12 and above used heroin in the past year (Jones et al., 2015). In Europe, the estimated annual 
heroin use prevalence is 4 per 1,000 aged 15-64 (EMCDDA, 2015) and 7.3 per 1,000 among 
people aged 16-64 in England (Hay et al., 2014).  
Opioid use disorder (OUD), and the conceptually identical ‘opioid dependence’, is a debilitating and 
often chronic bio-behavioural disorder (DSM-5; American Psychiatric Association, 2013; ICD-10; 
WHO, 2016). People with OUD typically use illicit heroin and/or non-medical opioid pharmaceutical 
products, developing physiologically dependence and strong motivational urges. Around one 
quarter of opioid users develop OUD (Gable, 1993;  Anthony et al., 1994). Left untreated, OUD 
typically follows a chronic course causing substantial health, social and economic problems (Hser 
et al., 2001; Grella and Lovinger, 2011; Hser et al., 2015). In the classic Grella and Lovinger study, 
half of the sample died and a quarter did not experience any sustained improvement in their drug 
use (Grella and Lovinger, 2011).  
The OUD population is far from homogenous. Several behaviours are associated with increasing 
severity of the disorder (Marsden et al., 2014) and treatment effectiveness may vary between sub-
populations. For example, drop-out is more likely among patients with comorbid psychiatric 
conditions and more criminal justice involvement in the year before treatment, and less likely 
among those living with dependent children (Evans et al., 2009). Ethnic minority populations have 
been reported to have a lower rate of treatment episode completion (Mennis and Stahler, 2016). 
An important sub-population are polydrug users, typically involving concurrent use of one or more 
of the following: alcohol, cocaine powder, smokeable (crack) cocaine and benzodiazepines (Darke 
and Hall, 1995; Monga et al., 2007; Harrell et al., 2012; Kuramoto et al., 2011). Heroin smokers 
who use crack cocaine are substantially less likely to be infected with Hepatitis C virus that those 
who inject heroin (Harrell et al., 2012). Opioid-polydrug users have been observed to have greater 
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health and social problems (Leri et al., 2003) and a relatively poorer response to OUD treatment 
(Williamson et al., 2006; Marsden et al., 2011, 2009).  
The majority of countries with a high prevalence of OUD have an array of well-developed treatment 
services. The opioid medications methadone and buprenorphine are front-line, randomised-
controlled trial supported pharmacotherapies (Mattick et al., 2014, 2009). Some OUD patients may 
receive psychosocial interventions without opioid psychotherapy. Interventions are typically 
provided by specialist community, primary care and hospital providers. Inpatient withdrawal 
management and drug-free residential rehabilitation services are also available. In addition to case 
management, national clinical guidelines recommend psychosocial interventions to address 
cognitive and behavioural symptoms of OUD (e.g. National Institute for Clinical Excellence, 2007).  
Internationally, there have been several longitudinal cohort studies of the effectiveness of these 
interventions as delivered under routine conditions by public treatment systems (e.g. Simpson and 
Sells, 1990; Stewart et al., 2002; Darke et al., 2007; Marsden et al., 2009; White et al., 2015). 
Taken together, these studies conclude that treatment is associated with reduced opioid use, drug 
injecting, and offending behaviour, and improvements in health (including a substantially reduced 
risk of fatal overdose), social functioning and employment.  
Longitudinal cohort studies are time consuming and expensive. Public accountability means that 
the commissioners of publicly funded services need information on the effectiveness of treatment 
as it is delivered. Various proxy measures of outcome have been used in treatment systems 
research, including unsanctioned discharge (drop-out) from treatment and retention (Brorson et al., 
2013; Stark, 1992; Faggiano et al., 2003). A commonly used measure is the proportion of patients 
treated who complete treatment successfully (Alterman et al., 2001). This indicator is associated 
with reduced drug use (Evans et al., 2009; Kornør and Waal, 2005), increased employment (Lang 
and Belenko, 2000; Zarkin et al., 2002; Evans et al., 2009; Sung and Chu, 2011), lower arrests and 
incarceration (Campbell et al., 2007; Evans et al., 2009; Gifford et al., 2014), and a reduced 
likelihood of readmission to treatment services (Luchansky et al., 2000). In the US, substantial 
inter-state (Arndt et al., 2013) and regional variation in completion rates have been reported 
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(Hawkins et al., 2014), and this is now monitored at the federal/government level (Stahler et al., 
2016). 
The ‘successful completion’ indicator has a key limitation – it does not capture the extent to which 
treatment benefit is enduring. This is important because relapse is common, affecting 50-60% of 
people within six months after leaving treatment (McLellan et al., 2005). The process of achieving 
stable recovery from OUD may involve several cycles of treatment over a decade or more (Dennis 
et al., 2005; Hser et al., 1997).  
To fully assess the effectiveness of treatment systems, national administrative databases need to 
be able to capture this process, yet the requirements of such systems are difficult to implement. In 
the US, the absence of a patient consent prevents linkage across consecutive treatment episodes. 
At the national level, the impact of this is twofold: it is not possible to objectively assess whether an 
individual has previously engaged in treatment (an indicator of patient-level complexity (Marsden et 
al., 2012; Siguel and Spillane, 1978). It is also not possible to determine whether a patient’s 
successful completion status is enduring. 
England has a well-developed public treatment system for drug use disorders with service delivery 
involving specialist clinics in the National Health Service (NHS) and non-governmental sector. 
Services are commissioned by 149 local treatment systems across the country aligned to local 
government geographical boundaries. All public providers report clinical and effectiveness data to 
the National Drug Treatment Monitoring System (NDTMS). NDTMS is operated by Public Health 
England and provides outcome monitoring and performance benchmarking for each local system 
(see Marsden et al., 2009 for an operational description). The latest national report shows that 28% 
of people treated for OUD complete treatment successfully (Public Health England, 2016a).  
With temporal linkage of episodes, NDTMS can record re-presentation to treatment as a proxy 
remission indicator. To our knowledge, a ‘successful completion and no re-representation’ outcome 
measure has not been used in previous OUD treatment systems research. Accordingly, the aim of 
this study was to estimate the effectiveness of OUD treatment in England for OUD using this 
indicator and contrast the effectiveness of local treatment systems.  
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2.  Methods 
2.1  Design  
This was an English national, five-year, prospective, observational cohort study of publicly-funded, 
specialist treatment services for OUD reporting to the NDTMS, and reported following the STROBE 
guideline for observational research (Elm et al., 2007). The population for the study was all adults 
(≥18 years) diagnosed with OUD who presented for treatment in England between 1 April 2008 
and 31 March 2009.  
The study included all local treatment systems and all operational specialist community agencies in 
the NHS and third-sector providing pharmacotherapies, psychosocial interventions and adjunctive 
support services for OUD in community, inpatient (short-term medically supervised withdrawal), 
and residential (drug-free rehabilitation) settings. 
2.2 NDTMS database 
NDTMS captures a core dataset of all clients entering the treatment system, and is designed to 
record key information at each stage of the treatment process. An initial triage assessment is 
conducted by clinical staff at each treatment service during the first face-to-face meeting following 
referral to treatment which can, in the case of self-referrals for example, take place on the same 
day. Where a treatment need is clinically indicated, the substance(s) and patient demographics are 
recorded on NDTMS and an appointment for a treatment intervention is arranged. The mean 
waiting time to initiate this intervention is 2.2 days for OUD patients, and 98% start treatment within 
three weeks (Public Health England, 2016a). Each treatment intervention received is recorded on 
NDTMS (section 2.2.1). Treatment is not time-limited: patients are maintained in treatment for as 
long as clinically indicated (section 2.2.2). 
2.2.1 OUD treatments  
The opioid pharmacotherapies included methadone, buprenorphine and also naltrexone. 
Psychosocial interventions such as contingency management and motivational interviewing 
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complement pharmacotherapy and target underlying psychological aspects of dependence.  In 
addition to opioid pharmacotherapy and/or psychosocial interventions, a patent’s treatment 
programme could include adjunctive ‘recovery support’ services, including: facilitated access to 
mutual aid; complementary therapies; and family, housing, employment, education and training 
supports. 
2.2.2 Treatment episodes and journeys 
Following the NDTMS reporting protocol, each patient-level ‘treatment journey’ comprised: a single 
episode of pharmacotherapy or psychosocial intervention provided by a clinic; enrolment in 
concurrently delivered medication and psychosocial interventions (from one or more clinics); or a 
continuing care package in which an intervention was followed by one or more further 
interventions. Episodes commencing after 21 days are classified   as a new treatment journey 
(Public Health England, 2015). Recovery support services are offered concurrently or following a 
treatment episode. Patients are regularly reviewed, treatment provision changes, and at the end of 
the ‘treatment journey’, patients who overcome their dependence are successfully discharged from 
the treatment system. 
When a patient was discharged from treatment, one of the following exit reasons was recorded: 
successful completion; drop-out (patient left treatment without discussion or before completing their 
care plan); unsuccessful transfer (patient was referred to another treatment service but does not 
enter treatment within 21 days); incarceration (treatment is prematurely terminated due to criminal 
justice action); or patient died. After this point, further treatment was classified as a new treatment 
journey. 
2.3  Outcome measure 
The outcome measure for the study combined two components: successful completion and no re-
presentation. Successful completion was assigned to each patient that was reported by the clinic 
as meeting the following criteria within five years (ending 31 March 2014):  
 in remission from OUD;  
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 abstinent from all opioids and crack cocaine;  
 completed all opioid pharmacotherapy and psychosocial interventions;  
 met all care plan goals, with mutual agreement to exit treatment.  
For the ‘no re-presentation’ element of the outcome measure, we judged that a six-month period 
was reasonable (ending 30 September 2014). Therefore, the effectiveness measure was assigned 
to those patients who met the above criteria at exit from treatment and did not re-present for any 
treatment within six months (‘successful completion, no re-representation’, SCNR for economy 
herein). 
2.4  Covariates  
We followed an integrated variable-centred and person-centred approach to evaluate treatment 
effectiveness for OUD using the following patient demographic, clinical information and previous 
treatment exposure (all recorded at initial assessment): 
Demographic. Sex; age (centred at 18 years and grouped in five-year increments); Black and 
Minority Ethnicities (BME: a legal monitoring requirement (Race Relations (Amendment) Act, 
2000)); employed; housing problems (defined primarily as having no fixed abode, but can also 
include squatting, short-term hostel/B&B, staying with friends/relatives; [(homeless, herein]). 
Social deprivation. Local area deprivation was measured by the Indices of Multiple Deprivation 
(IMD; (Department for Communities and Local Government, 2007)). IMD data were linked to 
NDTMS based on the patient’s residential postcode district or the location of their first treatment 
provider in instances of missing postcode information. 
Injecting status.  Three levels of injecting status are recorded at the start of treatment: never 
injected; lifetime history of injecting, and current injector. 
Career length. The number of years between first initiating opioid use and enrolment in the index 
treatment journey (length of the substance-using career). This measure was mean centred and 
coded in five-year increments.   
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Treatment history. Referral route into treatment was categorised into whether the patient was self-
referred, referred via the criminal-justice system or other (e.g., referral from health service or 
substance abuse service). Whether an individual had previously accessed treatment was also 
included. 
2.5  Statistical analysis 
All analyses were done in Mplus (version 7.11) and Stata (version 13.1).   
2.5.1 Drug use sub-populations 
Given anticipated heterogeneity in drug use profile of the OUD population at presentation to 
treatment (Monga et al., 2007; Public Health England, 2016a), we used latent class analysis (LCA) 
in Mplus to identify discrete sub-populations of OUD patients who presented for treatment with 
concurrent disorder with one or more of the following 6 substances: crack cocaine; cannabis; 
alcohol; non-medical opioids; stimulants (powder cocaine and d-amphetamine) and 
benzodiazepines.  
The LCA was iterative with an unconditional 1-class model initially fit to the data and sequentially 
increased to a 6-class model. Each model used 5,000 random sets of starting values to guard 
against convergence on local maxima (McLachlan and Peel, 2000) and a minimum class size of 
5% of the cohort was set for utility (Willey et al., 2016; Borders and Booth, 2012). Class 
identification was informed by posterior fit statistics, including the Bayesian and Akaike information 
criteria and entropy. A multinomial logistic regression was then used to characterise the latent 
classes on the patient-level characteristics. Given the hierarchical structure of the study, with 
patients clustered in treatment services and services clustered in local treatment systems, 
confidence intervals (CI) were calculated using robust standard errors.  
2.5.2 Outcome analysis 
A three-level, multivariable logistic regression was used for the analysis of the outcome measure 
(Stata command: meqrlogit). The complete-case model contained the following random intercepts: 
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patients (level one); treatment services (level two); and local treatment system (level three). Model 
discrimination and variation (at level two and three) was estimated by c-index (Hanley and McNeil, 
1982), and intra-cluster correlation (ICC), respectively.  
Reflecting the hierarchical design of the study (Hofmann, 1997; Heo and Leon, 2008) and with 
alpha, statistical power and a medium effect size on the outcome measure pre-set (0.05, 0.90 and 
2 = 0.15, respectively [Cohen, 1988]), we ensured that that there were at least 15 cases per 
covariate in the regression analysis to minimise overfitting (Green, 1991; Babyak, 2004).   
With no contrary evidence that data loss was missing-at-random (Little and Little, 2002), a multiply 
imputed dataset was computed by chained equations (Stata command: mi: impute chained). An 
all-case multivariate logistic model was run to check on potential bias and loss of precision (Sterne 
et al., 2009). To achieve a relative efficiency above 98% (Rubin, 1987), and to ensure that 
reduction in power was less than 1% (Graham et al., 2007), 20 datasets of probabilistic values 
were created, each analysed separately, and then combined using Rubin’s rules.  
2.5.3 Analysis of local treatment systems  
A fixed-effects approach was used to determine the relative effectiveness of each local treatment 
system because random intercepts could mask real variation in achieving the outcome (Marsden et 
al., 2012). For each treatment system, predicted outcome probabilities were summed across 
patients and divided by the number of patients treated in the area. A risk-adjusted outcome rate 
was then calculated by dividing the expected rate by the observed rate and multiplying this by the 
national average.  
A funnel plot with 95% control limits (Spiegelhalter, 2005) then identified areas where outcome 
performance was better or worse than expected (where the area was located above or the control 
limit, respectively).  Local treatment systems rates of opiate prevalence, offending and drug-related 
deaths were contrasted by incidence-rate ratio.  
Outcome performance was contrasted using pooled estimates of the rate of opiate users per 
thousand inhabitants (Hay et al., 2010), incidence of drug related deaths per million inhabitants 
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(Public Health England, 2016b) and the criminal offence rate per thousand inhabitants (Office for 
National Statistics, 2016) The offending rate was based on the local area population estimates 
used in the development of the opiate prevalence estimates (Hay et al., 2010). 
3.  Results 
3.1  Study cohort and follow-up 
The population for the study was all adults (≥18 years) diagnosed with OUD who presented for 
treatment in England between 1 April 2008 and 31 March 2009 (N=56,156). As 1,799 (3.2%) 
people did not commence treatment by 31 March 2014, they were removed from further analyses.   
Patients in the cohort (n = 54,357) commenced treatment for OUD in 1,421 specialist clinics and 
primary care teams in the National Health Service (NHS) and the non-governmental sector 
(median of 12 patients per service; IQR 3-45), and in all 149 local treatment systems in England 
(median 302 patients per area; interquartile range [IQR] 184-470]).  
At the end of the five-year period, 7,890 people (14.5%) were continuously enrolled in treatment for 
OUD. Given the aims of the present study, this group was removed. Among the final all-case 
cohort (n = 46,467), 9,007 patients (19.4%) had missing observations on one or more covariates, 
yielding a complete-case cohort of 37,460. The covariate with the highest level of missing data was 
length of heroin use career (11.4%), followed by employment status (9.1%), housing status (3.4%) 
and injecting (3.4%). 
3.2 Drug use sub-populations 
At clinical assessment, 67% of patients had a concurrent substance use disorder, as follows: crack 
cocaine (44.1%), cannabis (14.1%), alcohol (13.3%), other illicit opioids (11.4%), benzodiazepines 
(9.4%) and other stimulants (8.8%).   
Table 1 displays the results of the LCA models. The value of each information criterion (Akaike, 
Bayesian and adjusted Bayesian) reduced as the number of classes increased, indicating 
successively better fitting models. The bootstrapped likelihood ratio test confirmed that each model 
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was a statistically better fit than the preceding one. Entropy was high (>0.8) for all except the 3-
class solution, which reflected relative uncertainty in the assignment of individuals to the third 
class. The 5-class and 6-class solutions resulted, however, in at least one class with less 5% of the 
cohort. Accordingly, we judged that a 4-class solution best identified the heroin and other drug use 
sub-populations at treatment admission, and labelled these as follows: 
 Class 1 (n=30,339, 56%: heroin low level concurrent drug use disorders); 
 Class 2 (n=2,794, 5%: heroin, crack, alcohol); 
 Class 3 (n=17,907, 33%: heroin, crack); 
 Class 4 (n=3,257, 6%: heroin, crack, cannabis). 
3.3  Characteristics of the cohort  
Table 2 shows the demographic and clinical characteristics of the cohort and the results of the 
multinomial logistic regression analysis of the profile of the drug problem classes on socio-
demographic, injecting, heroin career and treatment referral characteristics (with the heroin and 
low concurrent drug use disorders [class 1] as the referent).  
There were relatively less employment and more homelessness among the members of classes 2, 
3 and 4. Class 4 was also relatively more likely to be referred to treatment from the criminal justice 
system (35.3%) and have previous OUD treatment (50.4%).  
3.4  Treatment exposure and status at exit  
Patients in the cohort received a median of 31.0 weeks of treatment (IQR 12.6-80.3) and 13,360 
(28.8%) successfully completed their treatment journey (Table 3). One-third (32.1%) of discharged 
patients were readmitted for further treatment for substance use disorders within six months.  
Readmission was more likely for those who were incarcerated (re-admission rate 45.2%; odds ratio 
[OR] 2.67; 95% CI 2.50-2.82), dropped out (re-admission rate 34.8%; OR 1.72; 95% CI 1.63-1.81), 
or transferred unsuccessfully to another SUD treatment service (re-admission rate 28.3%; OR 
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1.27; 95% CI 1.20-1.35) compared with those who completed treatment successfully (re-admission 
rate 23.7%). 
Relative to Class 1, patients assigned to Class 2 and Class 4 were less likely to have received 
opioid pharmacotherapy, Class 4 was more likely to have received psychosocial interventions, and 
Class 2 received more in-patient services. Class 1 received the least amount of residential services 
and was retained in treatment longer than any other class. Class 3 reported more incarceration, 
unsuccessful transfers and dropouts, but less deaths, while Class 2 had fewer incarcerations but 
more drop outs. There were relatively fewer deaths in Class 4.  
3.5 Successful completion of treatment and no re-presentation within six months 
Overall, 21.9% of the cohort (10,194) attained the SCNR outcome (Table 3). Class 3 were less 
likely to achieve the outcome. After negative multi-collinearity screening for all covariates, the 
results of the unadjusted, covariate adjusted complete-case (n=37,460) and multiply-imputed, all-
case (n=46,467) analyses are shown in Table 4.  
The complete- and all-case models yielded very similar covariate estimates. In the all-case model, 
with statistically significant adjustment for clustering effects associated with treatment agency and 
local treatment system (ICC 0.13 and 0.17, respectively) there was satisfactory discrimination 
between patients who achieved the SCNR outcome (c-index 0.74; 95% CI 0.74-0.75).  
There was an increased likelihood of positive outcome among older patients, those with pre-
treatment employment, and those who with longer time enrolled in treatment (particularly for more 
than 2 years; adjusted odds ratio [AOR] 2.60; 95% CI 2.43-2.78).  
A negative outcome was associated with men, patients who were homeless before admission and 
in areas of greater social deprivation (gradient with likelihood lowest at highest quintile; AOR 0.77; 
95% CI 0.70-0.85); drug injectors; those referred from the criminal justice system; those with 
previous treatment for OUD; those with shorter heroin using career; and members of class 3.  
3.6 Comparison of local treatment systems 
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Following risk-adjustment, 14 of 149 local treatment systems were classified as achieving 
performance that was better than expected on the SCNR outcome, and 38 local treatment systems 
achieved performance that was worse than expected (Figure 1). In comparison to the better 
performing areas, these 38 areas were characterised with a higher estimated level of opiate use in 
the local population (an extra 4.1 (95% CI 4.0-4.2) opiate users per thousand population), a higher 
level of drug-related offences (an extra 28.5 (95% CI 28.1-28.8) offences per thousand population), 
and more drug-related deaths (an extra 5.9 (95% CI 5.9-5.9) deaths per thousand population) 
(Table 5). 
4.  Discussion 
Over the five-year observation period, we observed that nearly one in three patients successfully 
completed treatment for OUD. Reinforcing previous research (Luchansky et al., 2000), patients 
who successfully completed treatment were least likely to be re-admitted to treatment within a 
subsequent six month period. In our national population of patients accessing publicly-funded 
treatment, one in five achieved a sustained benefit from treatment.  
Other studies have noted two (Shand et al., 2011), three (Harrell et al., 2012; Monga et al., 2007), 
five (Kuramoto et al., 2011), or eight (Patra et al., 2009) latent class structures.  Our analysis of 
polydrug dependence in patients seeking treatment for OUD in England revealed a four class 
structure. Crack cocaine was a defining characteristic in three of these classes, with one class 
being further classified with alcohol dependence and another classified with cannabis dependence. 
It is interesting to note that the only crack cocaine class without alcohol or cannabis dependence 
had worse outcomes than the heroin with low polydrug class.  
4.1.  Integration with the literature 
Unlike other large-scale studies on treatment completion (Arndt et al., 2013; Mennis and Stahler, 
2016), in our unadjusted models patients from Black and Minority Ethnicities (BME) were more 
likely to recover.  After controlling for other socio-economic factors, however, this disparity no 
longer held, highlighting the importance controlling for employment and stable housing (Saloner 
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and Lê Cook, 2013; Hawkins et al., 2014). Our findings provide general support for the construct of 
‘physical capital’ (Cloud and Granfield, 2008) playing a major role in recovery from heroin use 
disorder, as employment and stable housing were found to significantly affect the likelihood of 
recovery. The finding that increased time spent engaged in treatment increases the likelihood of 
successful completion aligns with previous research (Hubbard et al., 2003; Simpson and Sells, 
1990) and provides evidence that OUD treatment should not be time-limited (Advisory Council on 
the Misuse of Drugs, 2014). 
After controlling for patient-level and area-level deprivation predictors of outcome, local treatment 
systems that were performing significantly below the expected rate also appeared to have a much 
larger opiate using population and, presumably as a result of this, a higher rate of both offending 
and drug-related deaths. We are not able to determine a mechanism for this association. There 
may be social network influences in operation. For example, social networks can influence both a 
transition to injecting heroin (Neaigus et al., 2006) and the decision to share injecting equipment 
(De et al., 2007). Heroin users who have achieved abstinence often cite moving away from drug-
using social networks and receiving support from non-using friends as a contributory factor to their 
success (Best et al., 2008). 
4.2.  Strengths and limitations 
The main study strength is the national, large scale, long-term follow-up of all individuals accessing 
treatment for heroin use disorder in England and the utilisation of the national administrative 
database to monitor relapse. Unlike other comprehensive administrative datasets (Sahker et al., 
2015; Alterman et al., 2001; Stahler et al., 2016), NDTMS has patient-level identifiers that enable 
cross-referencing with subsequent treatment admissions. This utility provides not only an objective 
summative measure of the sustainability of recovery in this population, it also enables national 
administrative systems to objectively capture whether patients had previously accessed treatment 
services, which is an important negative predictor of treatment outcome (Siguel and Spillane, 1978; 
Marsden et al., 2012). 
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Several study limitations are also acknowledged: firstly, our analysis of OUD sub-populations is 
based on clients entering the treatment system in 2008/09. It is possible that since this period, with 
the rise of novel psychoactive substances for example, a different class structure would emerge for 
clients currently accessing treatment. Second, we were not able to access data from the national 
deaths registry or the national prisons system, and there remains a concern that at least some of 
our patients who did not re-present to treatment were simply unable to. Third, while all available 
covariates in NDTMS were screened in the present analysis, other covariates could further 
elucidate the likelihood of sustaining recovery, including treatment motivation (Simpson and Joe, 
1993), engagement (Simpson et al., 1995) and other recovery strengths (Gossop et al., 2002). 
Fourth, it is possible that other interventions were experienced by the patients in this cohort, such 
as privately-funded residential treatment or attending Alcoholics Anonymous, but these 
interventions are not captured by NDTMS and it is not possible to assess the potential impact 
these may have had. 
4.3.  Conclusions 
Relapse requiring treatment is relatively common in the six months following treatment completion.  
This study highlights the importance of including re-presentation to treatment as a summative 
measure of the effectiveness of local treatment systems. We note a sizeable proportion of 
individuals, nearly one in seven, who have been continuously engaged in treatment throughout the 
five-year observation period. The next questions for our research group are whether, and to what 
degree, heroin and other drug use changes throughout this time period; how change in heroin use 
relates to change in other drugs; whether five-year in-treatment change predicts subsequent 
successful completion of treatment, and to examine the longitudinal inter-relationship between 
substance use, employment and housing. 
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Table 1. Unconditional latent class analysis of drug use at presentation to treatment (n=54,347) 
 
      Model a       
Parameter Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 
No. of parameters   6    13    20    27   34   41 
AIC 266,371.29 264,740.91 262,525.26 261,201.63 260,527.17 260,033.40 
BIC 266,424.71 264,856.65 262,703.32 261,442.02 260,829.88 260,398.43 
aBIC 266,405.65 264,815.33 262,639.76 261,356.22 260,721.83 260,268.13 
aBIC change (%) - -0.60 -0.82 -0.49 -0.24 -0.17 
Entropy - 0.999 0.718 0.830 0.861 0.857 
BLRT - -133,179.65 -132,357.45 -131,242.63 -130,573.82 -130,229.58 
BLRT reduction (%) - - 0.62 0.84 0.51 0.26 
Class (probability)       
1 1.00 (1.00) 0.44 (1.00) 0.06 (0.99) 0.56 (0.83) 0.29 (0.99) 0.01 (0.71) 
2 - 0.56 (1.00) 0.38 (1.00) 0.05 (0.99) 0.04 (0.97) 0.55 (0.79) 
3 - - 0.56 (0.69) 0.33 (0.99) 0.05 (0.99) 0.04 (0.99) 
4 - - - 0.06 (0.99) 0.06 (0.99) 0.06 (0.99) 
5 - - - - 0.56 (0.84) 0.29 (0.99) 
6 - - - - - 0.05 (0.98) 
 
AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion;  
aBIC, sample-size adjusted BIC; BLRT, bootstrapped likelihood ratio test (all P < 0.00005). 
 
a For the following drugs: crack cocaine, cannabis, alcohol, other opioids, benzodiazepines and 
other stimulants.  
 
Classification based on most likely latent class membership.
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Table 2. Characteristics of the cohort and drug use sub-populations 
 
Covariate 
Total 
n           (%) 
 
Class 1 
n=30,339 
Class 2 
n=2,794 
Class 3 
n=17,907 
Class 4 
n=3,257 
Socio-demographic       
Male 41,099  (75.6) (76.5) (74.9) (73.0) (82.0) 
Age a 32.9  (7.8) 32.9 (7.9) 34.2 (7.9) 33.0 (7.5) 31.9 (7.9) 
Black/Minority Ethnic 7,342 (13.5) (10.9) (15.8) (15.9) (22.4) 
Employed 6,222  (12.5) (14.7) (8.1) (9.7) (11.4) 
Homeless 17,343  (32.9) (29.5) (43.1) (36.8) (35.1) 
Social deprivation:       
  Quintile 1 (lowest) 10,857  (20.0) (21.6) (19.9) (17.1) (20.4) 
   2 10,922  (20.1) (19.9) (21.9) (20.1) (20.3) 
   3 10,823  (19.9) (19.9) (23.3) (19.3) (20.2) 
   4  10,859  (20.0) (19.8) (18.9) (20.3) (20.6) 
  Quintile 5 (highest) 10,896  (20.0) (18.7) (16.0) (23.2) (18.5) 
Clinical        
Heroin career a 11.4  (7.5) (7.6) (8.3) (7.2) (7.4) 
Drug injecting:       
  Never 17,715  (33.6) (32.8) (32.5) (33.1) (44.5) 
  Lifetime 18,004  (34.2) (34.9) (35.4) (33.5) (30.4) 
  Current 16,996  (32.2) (32.3) (32.1) (33.4) (25.0) 
Referral source:       
  Other 17,453  (32.1) (35.0) (35.1) (27.6) (27.2) 
  Self 20,570  (37.8) (39.4) (37.6) (35.2) (37.5) 
  Criminal justice 16,334  (30.0) (25.6) (27.3) (37.1) (35.3) 
Previous OUD treatment: 30,212  (55.6) (55.6) (52.4) (57.0) (50.4) 
  < 6 months 20,835  (38.3) (35.3) (45.1) (41.4) (44.1) 
  6 months to < 1 year 8,917  (16.4) (16.1) (16.4) (16.9) (17.0) 
  1 year to < 2 years 8,014  (14.7) (15.4) (14.3) (13.6) (14.9) 
  2 years to 5 years 16,591  (30.5) (33.2) (24.3) (28.1) (24.0) 
           
Class 1: Heroin and low likelihood of problem substance use; 
Class 2: Heroin, problem crack cocaine and alcohol use; 
Class 3: Heroin and crack cocaine use; 
Class 4: Heroin and crack and cannabis use. 
 
Figures in parentheses in table are percentages unless otherwise stated. 
 
a Year (SD) 
Emboldened percentages and means are statistically significant (P < 0.05) from multivariable, 
multinomial logistic regression (Class 1: referent). 
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Table 3. Treatment interventions received, by treatment leavers, SCNR outcome and latent class 
 
Treatment characteristics 
Total 
(n=46,467) 
Class 1: 
Heroin, low 
poly-substance 
(n=25,469) 
Class 2: 
Heroin, 
crack, alcohol 
(n=2,496) 
Class 3: 
Heroin, crack 
(n=15,566) 
Class 4: 
Heroin, crack, 
cannabis 
(n=2,936) 
Exposure – interventions received      
  Opioid pharmacotherapy, n (%) 36,122 (77.7) 20,377 (80.0) 1,602 (64.2) 12,082 (77.6) 2,061 (70.2) 
  Psychosocial interventions, n (%) 25,742 (55.4) 13,682 (53.7) 1,537 (61.6) 8,694 (55.9) 1,829 (62.3) 
  In-patient withdrawal management, n (%) 3,010 (6.5) 1,546 (6.1) 275 (11.0) 1,021 (6.6) 168 (5.7) 
  Residential rehabilitation, n (%) 1,620 (3.5) 711 (2.8) 167 (6.7) 617 (4.0) 125 (4.3) 
Median weeks to discharge      
  Successful completion (IQR)* 39.5 (15.3-109.9) 46.0 (16.6-119.7) 30.9 (14.9-79.1) 34.1 (14.0-99.3) 31.9 (14.6-90.4) 
  Died, (IQR) 81.0 (32.0-147.9) 83.4 (35.7-150.0) 51.4 (16.4-177.2) 81.1 (32.0-140.3) 65.3 (11.0-142.1) 
  Incarcerated, (IQR) 35.4 (14.7-82.6) 38.4 (16.0-85.9) 33.9 (13.3-87.0) 32.3 (13.3-79.0) 34.4 (13.0-73.9) 
  Unsuccessful transfer, (IQR) 32.4 (12.9-79.3) 35.0 (13.3-84.3) 27.1 (10.3-74.9) 30.7 (12.3-75.6) 27.6 (11.1-66.3) 
  Dropped out, (IQR) 22.9 (9.9-57.7) 25.1 (10.7-61.9) 19.1 (9.1-46.7) 20.9 (8.9-52.7) 20.3 (9.7-55.9) 
  Total, (IQR) 31.0 (12.6-80.3) 34.3 (13.3-87.0) 25.6 (11.8-67.9) 28.0 (11.6-73.4) 27.0 (11.9-69.9) 
Treatment exit status      
  Successful completion, n (%) 13,360 (28.8) 7,675 (30.1) 718 (28.8) 4,066 (26.1) 901 (30.7) 
  Died, n (%) 684 (1.5) 435 (1.7) 52 (2.1) 182 (1.2) 15 (0.5) 
  Incarcerated, n (%) 7,425 (16.0) 3,820 (15.0) 299 (12.0) 2,845 (18.3) 461 (15.7) 
  Unsuccessful transfer, n (%) 8,385 (18.1) 4,498 (17.7) 449 (18.0) 2,922 (18.8) 516 (17.6) 
  Dropped out, n (%) 16,613 (35.8) 9,041 (35.5) 978 (39.2) 5,551 (35.7) 1,043 (35.5) 
Treatment outcome       
  Successful completion and no re- 
    presentation within six months, n (%) 
10,194 (21.9) 5,882 (23.1) 566 (22.7) 3,063 (19.7) 683 (23.3) 
 
 Emboldened percentages and means are statistically significant (P < 0.05) from multinomial logistic regression (Class 1: referent). 
* IQR = interquartile range 
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Table 4. Unadjusted and multi-level, complete-case and all-case multivariable logistic regression 
of SCNR outcome  
 
Covariates 
Unadjusted 
OR (95% CI) 
(n=37,460) 
Complete-case  
AOR (95% CI) 
(n=37,460) 
All-cases  
AOR (95% CI) 
(n=46,467) 
Socio-demographic    
Male 0.87 (0.82, 0.92) 0.88 (0.83, 0.94) 0.88 (0.83, 0.93) 
Age 1.07 (1.06, 1.09) 1.09 (1.07, 1.11) 1.09 (1.07, 1.11) 
BME 1.11 (1.03, 1.20) 1.05 (0.97, 1.14) 1.02 (0.94, 1.09) 
Employed 1.46 (1.36, 1.58) 1.24 (1.15, 1.34) 1.27 (1.18, 1.37) 
No fixed abode 0.74 (0.70, 0.79) 0.85 (0.80, 0.91) 0.86 (0.81, 0.91) 
Deprivation: 
   Quintile 2 0.88 (0.80, 0.96) 0.93 (0.84, 1.02) 0.94 (0.86, 1.02) 
Quintile 3 0.82 (0.74, 0.90) 0.91 (0.82, 1.00) 0.91 (0.83, 1.00) 
Quintile 4 0.79 (0.71, 0.87) 0.84 (0.76, 0.93) 0.86 (0.78, 0.94) 
Quintile 5 (highest) 0.63 (0.57, 0.70) 0.74 (0.67, 0.83) 0.77 (0.70, 0.85) 
Clinical    
Injecting: 
   Previously injected 0.81 (0.76, 0.86) 0.87 (0.81, 0.93) 0.86 (0.81, 0.91) 
Currently injector 0.59 (0.55, 0.63) 0.64 (0.60, 0.69) 0.64 (0.60, 0.69) 
Referral route: 
   Self 0.95 (0.88, 1.01) 0.96 (0.90, 1.03) 0.97 (0.92, 1.04) 
Criminal justice 0.58 (0.54, 0.63) 0.68 (0.63, 0.74) 0.68 (0.63, 0.73) 
Drug use class: 
   Class 2: Heroin, crack & alcohol 0.92 (0.81, 1.03) 1.02 (0.90, 1.15) 0.97 (0.87, 1.08) 
Class 3: Heroin & crack 0.82 (0.77, 0.87) 0.92 (0.86, 0.98) 0.90 (0.85, 0.95) 
Class 4: Heroin, crack & cannabis 0.99 (0.89, 1.11) 1.08 (0.97, 1.20) 1.02 (0.92, 1.12) 
Previously treated 0.64 (0.61, 0.67) 0.66 (0.62, 0.69) 0.66 (0.63, 0.70) 
Heroin career  0.99 (0.97, 1.00) 0.97 (0.95, 0.99) 0.97 (0.95, 0.99) 
Time in index treatment journey: 
   6 months to < 1 year 1.28 (1.19, 1.39) 1.28 (1.19, 1.38) 1.32 (1.23, 1.41) 
1 year to < 2 years 1.43 (1.33, 1.55) 1.40 (1.29, 1.51) 1.39 (1.30, 1.49) 
2 years to 5 years 2.70 (2.51, 2.90) 2.59 (2.41, 2.79) 2.60 (2.43, 2.78) 
Model statistics 
   Constant - 0.38 (0.33, 0.43) 0.39 (0.34, 0.44) 
Wald X2 (d.f. = 21) - 1,538 1,834-1,854 
LR test X2 (d.f. = 2) - 938 1,342-1.349 
Random effects parameters (ICC):    
 Treatment system (Level 3)  - 0.01 (0.00, 0.02) 0.17 (0.11, 0.27) 
 Treatment agency (Level 2)  - 0.13 (0.11, 0.15) 0.13 (0.11, 0.15) 
 
SCNR, ‘successful completion of treatment journey and no representation to treatment within six 
months’; OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; d.f., degrees of 
freedom; ICC, intra-class correlation coefficient. 
 
Emboldened percentages and means are statistically significant (P < 0.05) 
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Table 5. Population estimates by local treatment system outcome performance, England 
  
  
Estimates  
All local systems 
(n=149) 
Performance 
better than 
expected (n=14) 
Performance 
worse than 
expected (n=38) 
Incidence 
rate 
difference 
 
Median of 
population aged 
16-64 (interquartile 
range) a 
172,000 
(127,100-272,700) 
210,550 
(171,250-433,725) 
170,100 
(140,625-219,725) 
 
- 
 
Number of opiate 
users per 1,000 
(95% CI) a 
 
7.7  
(6.5-9.0) 
 
6.3  
(5.0-7.6) 
 
10.4  
(9.1-11.9) 
 
4.1  
(4.0-4.2) 
 
Offence rate per 
1,000 (95% CI) b 
 
106.3  
(106.2-106.4) 
 
97.5  
(97.2-97.8) 
 
126  
(125.7-126.2) 
 
28.5  
(28.1-28.8) 
 
Drug-related 
deaths per million 
(95% CI) c  
 
33.5  
(32.7-34.4) 
 
32.9  
(30.2-35.8) 
 
38.8  
(36.9-40.8) 
 
5.9  
(5.9-5.9) 
 
 
a (Hay et al., 2010) 
b (Office for National Statistics, 2016) 
c (Public Health England, 2016b) 
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Figure 1. Funnel plot of outcome performance (SCNR rate) by local treatment system 
 
 
 
 
 
NB: The horizontal line is the national average for the SCNR outcome. The curved lines are the 
upper and lower 95% confidence interval. Each black dot represents a local treatment system.  
Local systems lying above the upper CI have an SCNR outcome performance that is better than 
average after risk-adjustment. Local systems lying below the lower CI have an SCNR outcome 
performance that is worse than average after risk-adjustment.  
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